The Role of Gemcitabine in First-Line Treatment of Advanced Ovarian Carcinoma

Seminars in Oncology

Volumn 33, Issue SUPPL. 6, 2006, Pages 26-32

  Thigpen, Tate ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HUMAN; LAPAROTOMY; LUNG INJURY; LUNG TOXICITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NEUTROPHIL; OVARY CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS;

EID: 33646543050     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.015     Document Type: Article

References (59)

1. Omura G., Blessing J., Ehrlich C., et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57 (1986) 1725-1730
2. Omura G., Bundy B., Berek J., et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 7 (1989) 457-465
3. The International Collaborative Ovarian Neoplasm (ICON) Group. ICON2. Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 352 (1998) 1571-1576
4. Thigpen T., Blessing J., Ball H., et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy. A Gynecologic Oncology Group study. J Clin Oncol 12 (1994) 1748-1753
5. Einzig A., Wiernik P., Sasloff J., et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10 (1992) 1748-1753
6. McGuire W., Rowinsky E., Rosenshein N., et al. Taxol. A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111 (1989) 273-279
7. Kohn E., Sarosy G., Bicher A., et al. Dose-intense taxol. high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86 (1994) 18-24
8. Verschraegen C., Sittisomwong T., Kudelka A., et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18 (2000) 2733-2739
9. Francis P., Schneider J., Hann L., et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12 (1994) 2301-2308
10. Kaye S., Piccart M., Aapro M., et al. Phase II trials of docetaxel (taxotere) in advanced ovarian cancer-An updated overview. Eur J Cancer 33 (1997) 2167-2170
11. Rose P., Blessing J., Ball H., et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma. A Gynecologic Oncology Group study. Gynec Oncol 88 (2003) 130-135
12. Piccart M., Gore M., Ten Bokkel Huinink W., et al. Docetaxel. An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87 (1995) 676-681
13. Kudelka A., Tresukosol D., Edwards C., et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 1552-1557
14. Creemers G., Bolis G., Gore M., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. Results of a large European phase II study. J Clin Oncol 14 (1996) 3056-3061
15. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
16. McGuire W., Blessing J., Bookman M., et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. J Clin Oncol 18 (2000) 1062-1067
17. Bookman M., Malmstrom H., Bolis G., et al. Topotecan for the treatment of advanced epithelial ovarian cancer. An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
18. Muggia F., Hainsworth J., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
19. Gordon A., Granai C., Rose P., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18 (2000) 3093-3100
20. Gordon A., Fleagle J., Guthrie D., et al. Recurrent epithelial ovarian carcinoma. A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
21. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78 (2000) 369-372
22. Rose P., Maxson J., Fusco N., et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma. A retrospective comparative study of single-agent dosages. Gynecol Oncol 82 (2001) 323-328
23. Campos S., Penson R., Mays A., et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 81 (2001) 206-212
24. Rose P., Blessing J., Mayer A., et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 405-410
25. Hoskins P., and Swenerton K. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12 (1994) 60-63
26. Seymour M., Mansi J., Gallagher C., et al. Protracted oral etoposide in epithelial ovarian cancer. A phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 69 (1994) 191-195
27. Markman M., Hakes T., Reichman B., et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 119 (1992) 55-57
28. Tuxen M., Lund B., Hansen O., et al. Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease. Int J Gynecol Cancer 7 (1997) 213-217
29. Friedlander M., Millward M., Bell D., et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9 (1998) 1343-1345
30. Shapiro J., Millward M., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer. Responses seen following platinum and paclitaxel. Gynecol Oncol 63 (1996) 89-93
31. Lund B., Hansen O., Theilade K., et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86 (1994) 1530-1533
32. George M., Heron J., Kerbrat P., et al. Navelbine in advanced ovarian epithelial cancer. A study of the French Oncology Centers. Semin Oncol 16 suppl 4 (1989) 30-32
33. Sorensen P., Hoyer M., Jakobsen A., et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81 (2001) 58-62
34. Burger R., DiSaia P., Roberts J., et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72 (1999) 148-153
35. Gershenson D., Burke T., Morris M., et al. A phase I study of daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70 (1998) 404-409
36. Bajetta E., Di Leo A., Biganzoli L., et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer. Activity in platinum-resistant disease. J Clin Oncol 14 (1996) 2546-2551
37. Look K., Muss H., Blessing J., et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 18 (1995) 19-22
38. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
39. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. Three-year results. J Natl Cancer Inst 92 (2000) 699-708
40. du Bois A., Luck H., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
41. Ozols R., Bundy B., Greer B., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. A Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
42. Thigpen T., Stuart G., du Bois A., et al. Clinical trials in ovarian carcinoma. Requirements for standard approaches and regimens. Ann Oncol 16 suppl 8 (2005) 13-19
43. Peters G., Bergman A., Ruiz van Haperen V., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 suppl 11 (1995) 72-79
44. Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol 29 suppl 1 (2002) 11-16
45. Belpomme D., Krakowski I., Beauduin M., et al. Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer. A phase II study. Gynecol Oncol 91 (2003) 32-38
46. Nogue M., Cirera L., Arcusa A., et al. Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 13 (2002) 839-845
47. Bauknecht T., Hefti A., Morack G., et al. Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer. A phase II study. Int J Gynecol Cancer 15 (2005) 180-181
48. Muggia F., Braly P., Brady M., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer. A Gynecologic Oncology Group study. J Clin Oncol 18 (2000) 106-115
49. Bookman M.A. Developmental chemotherapy in advanced ovarian cancer. Incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG 182). Semin Oncol 29 suppl 1 (2002) 20-31
50. Copeland L.J., Bookman M., and Trimble E. Clinical trials of newer regimens for treating ovarian cancer. The rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 90 (2003) S1-S7
51. Iaffaioli R.V., Tortoriello A., Facchini G., et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol 17 (1999) 921-926
52. Pedersen A.G. Phase I studies of gemcitabine combined with carboplatin or paclitaxel. Semin Oncol 24 suppl 7 (1997) 64-68
53. Gupta S.K., John S., Naik R., et al. A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaive advanced ovarian cancer. Gynecol Oncol 98 (2005) 134-140
54. Hansen S.W. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29 suppl 1 (2002) 17-19
55. Look K.Y., Bookman M.A., Schol J., et al. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer. A Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 93-100
56. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. Pilot study of outpatient paclitaxel, carboplatin, and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol 94 (2004) 719-724
57. du Bois A., Belau A., Wagner U., et al. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol 96 (2005) 444-451
58. Berkenblit A., Tung N., Kim Y., et al. Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin. Gynecol Oncol 89 (2003) 486-493
59. Harries M., Moss C., Perren T., et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 91 (2004) 627-632